Jacobs & Co. CA Sells 7,261 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Jacobs & Co. CA reduced its holdings in Edwards Lifesciences by 5.8%, selling 7,261 shares in the second quarter, which left them with 118,312 shares valued at approximately $9.25 million.
• Insider sales have been notable, with Larry L. Wood selling 8,950 shares and Daniel J. Lippis selling 4,114 shares, indicating a decrease in their respective holdings.
• The company reported earnings of $0.67 per share for the last quarter, exceeding analysts' expectations, and set guidance for Q3 2025 at 0.540-0.60 EPS.

Jacobs & Co. CA trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 118,312 shares of the medical research company's stock after selling 7,261 shares during the period. Jacobs & Co. CA's holdings in Edwards Lifesciences were worth $9,253,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $27,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter valued at about $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences during the first quarter valued at about $27,000. Rossby Financial LCC bought a new position in shares of Edwards Lifesciences during the first quarter valued at about $29,000. Finally, Costello Asset Management INC bought a new position in Edwards Lifesciences in the first quarter worth about $29,000. 79.46% of the stock is owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,014 shares of company stock worth $1,698,844. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $77.50 on Friday. The stock has a market cap of $45.50 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The firm's 50-day simple moving average is $78.92 and its two-hundred day simple moving average is $75.39.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Truist Financial increased their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Citigroup reissued a "buy" rating and issued a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Wells Fargo & Company increased their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $86.26.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.